Treatment of amyotrophic lateral sclerosis using botulinum toxin
A method for treating Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and/or a sacral nerve of the patient. The administration of the botulinum toxin prevents an overproduction of glutamate, Substance P, and CGRP in a sensory system and thereby inhibits a migration of the glutamate, Substance P, and CGRP to the motor system, which otherwise would cause neuroexcitatory toxicity that results in the death of motor neurons.
1. A method for treating Amyotrophic Lateral Sclerosis (ALS) in a patient in need thereof, comprising
administering botulinum toxin to the patient, thereby treating the Amyotrophic Lateral Sclerosis (ALS), wherein the administering for an adult comprises, by subcutaneous or intradermal injection, injecting 1-4 units to and/or around the vicinity of a trigeminal nerve, 1-4 units to and/or around the vicinity of a cervical nerve, lateral to the patient's spine, 1-4 units to and/or around the vicinity of a thoracic nerve, lateral to the patient's spine, 1-4 units to and/or around the vicinity of a lumbar nerve, lateral to the patient's spine, and/or 1-4 units to and/or around the vicinity of a sacral nerve, lateral to the patient's spine, and
monitoring if the patient's neuroexcitatory substances levels normalize.
2. The method of claim 1 , wherein the trigeminal nerve comprises an ophthalmic nerve, maxillary nerve, mandibular nerve, supraorbital nerve, supratrochlear nerve, infraorbital nerve, lacrimal nerve, nasociliary nerve, superior alveolar nerve, buccal nerve, lingual nerve, inferior alveolar nerve, mental nerve, an auriculotemporal nerve, lesser occipital nerve, a greater occipital nerve, or a combination thereof.
3. The method of claim 1 , wherein the cervical nerve comprises a c-2 nerve, c-3 nerve, c-4 nerve, c-5 nerve, c-6 nerve, c-7 nerve, c-8 nerve, or a combination thereof.
4. The method of claim 1 , wherein the thoracic nerve comprises a 1-2 nerve, t-3 nerve, t-5 nerve, t-6 nerve, t-7 nerve, t-8 nerve, 1-9 nerve, t-10 nerve, t-11 nerve, t-12 nerve, or a combination thereof.
5. The method of claim 1 , wherein the lumbar nerve comprises an 1-1 nerve, 1-2 nerve, 1-3 nerve, 1-4 nerve, 1-5 nerve, or a combination thereof.
6. The method of claim 1 , wherein the sacral nerve comprises an s-1 nerve, s-2 nerve, s-3 nerve, s-4 nerve, s-5 nerve, or a combination thereof.
7. The method of claim 1 , wherein the administered botulinum toxin comprises botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type E, botulinum toxin type F, botulinum toxin type G, a fragment thereof, a hybrid thereof, a chimera thereof, or a combination thereof.
8. The method of claim 1 , wherein a total dosage of the botulinum toxin for an adult who weighs about 150 lbs. is between about 1 unit and about 150 units.
9. The method of claim 8 , wherein a total dosage of the botulinum toxin for an adult, a child is adjusted for age, weight, or a combination thereof.
10. The method of claim 1 , wherein the neuroexcitatory substances are substance P, calcitonin gene-related peptide (CGRP) or glutamate.
11. The method of claim 1 , wherein the patient's neuroexcitatory substances level are blood levels.
12. The method of claim 1 , wherein the monitoring if the patient's neuroexcitatory substances levels normalize comprises monitoring if the patient's blood glutamate level normalizes.
13. The method of claim 12 , wherein a normal blood glutamate level is from about 40 to about 60 uM.
14. The method of claim 1 , wherein if the patient's neuroexcitatory substances levels fail to normalize, additional botulinum toxin is administered to the patient.
15. The method of claim 14 , wherein if the patient's neuroexcitatory substances levels fail to normalize even after administering the additional botulinum toxin, an antagonist to the neuroexcitatory substances is administered to the patient.
16. The method of claim 1 , wherein if the patient's neuroexcitatory substances levels fail to normalize, an antagonist to the neuroexcitatory substances is administered to the patient.
17. The method of claim 1 , wherein the monitoring if the patient's neuroexcitatory substances levels normalize occurs or two weeks after the administering botulinum toxin to the patient.
18. The method of claim 1 , further comprising monitoring the patient's physical symptoms.
19. The method of claim 18 , wherein if the patient's physical symptom continues, additional botulinum toxin or an antagonist to the neuroexcitatory substances is administered to the patient.
20. The method of claim 1 , wherein each of the subcutaneous or intradermal injection is bilateral.